Octapharma

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Octapharma AG
Type Private
Industry Pharmaceutical Industry
Founded 1983
Headquarters Lachen, Switzerland
Number of locations 45
Products octaplas, octagam,octagam10%, octanate, octanyne, octaplex, octavi SD Optimum, octalbin, uniplas, rhesonativ, aunativ, gammonativ, atenativ, gammanorm, nanotiv, octonativ, octanine F, wilate
See complete products listing.
Revenue Euro 1.154 billion (2013)[1]
Employees 5,514 (2013)[2]
Website www.octapharma.com

Octapharma AG is the largest privately owned human protein products manufacturer in the world. Founded in 1983 by Wolfgang Marguerre, Octapharma employs more than 5,500 people globally. Octapharma is owned by Wolfgang Marguerre and his three children, two of whom, Frederic Marguerre and Tobias Marguerre, sit on the management board. Octapharma's core business is the development and production of human proteins from human blood plasma and human cell-lines. It is headquartered in Lachen, Switzerland.

Products[edit]

Patients in over 100 countries are treated with products in the following therapeutic areas:

[3]

History[edit]

Octapharma was founded in 1983 on the principle of enhancing safety for patients. In the name Octapharma, the “octa” is derived from the Greek word for eight, named after the factor which is deficient in haemophilia A patients. Octapharma’s inaugural product was the first Factor VIII concentrate using what was then innovative solvent detergent virus inactivation technology.

The underlying principle of Octapharma’s R&D is the development of therapies based on human proteins either purified from human plasma or produced by recombinant technologies applied to human cell lines.

Research and Development[edit]

Current R&D Projects (April 2014)

  • Fully pharmaceutically licensed, SD-treated, freeze-dried, non-blood-type-specific plasma in bags
  • A new Fibrinogen product
  • Next generation Immunoglobulin
  • A human growth factor product
  • G-CSF (Granulocyte colony-stimulating factor, long acting)
  • Alpha-1-Antitrypsin
  • C1-Esterase-Inhibitor
  • Human coagulation factor VII

Production[edit]

Octapharma converts source plasma into plasma protein products through fractionation and processing. Octapharma owns five state-of-the-art production facilities in Austria, France, Germany, Sweden and Mexico.

Octapharma owns plasma centres in Europe and the United States. To fulfil increasing global demand and to exceed its ambitious goals, the company is increasing plasma availability by sourcing higher volumes of plasma and increasing the capacity of production plants to convert more source plasma into product.

Notes and references[edit]

See also[edit]

External links[edit]